HanAll Biopharma's antibody drug candidate for autoimmune diseases, "imeloprubart (IMVT-1402)," has achieved clinically meaningful therapeutic effects in patients with difficult-to-treat rheumatoid arthritis who had not responded to existing therapies.
Immunovant, HanAll Biopharma's global partner, disclosed the findings during its quarterly earnings announcement on Thursday (local time), releasing 16-week interim analysis results from an ongoing clinical trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA). The trial enrolled 170 patients who had failed to respond to two or more targeted therapies with different mechanisms of action, including conventional disease-modifying antirheumatic drugs (DMARDs), JAK inhibitors that block inflammatory signaling, and anti-TNF treatments.
According to the released data, at 16 weeks of imeloprubart dosing, ACR20—an indicator of patient symptom improvement—reached 72.7%, while ACR50 came in at 54.5%. ACR70, which signifies relief of severe symptoms, also showed a response rate of 35.8%, confirming the drug's potential as a treatment alternative. The drug also demonstrated excellent tolerability in terms of safety, with no new drug-related safety concerns observed.
Immunovant plans to release placebo-controlled clinical trial results in D2T RA patients, along with topline results from an early-stage trial in cutaneous lupus erythematosus (CLE), in the second half of this year. Imeloprubart is currently being developed for global regulatory approval across more than six autoimmune diseases, including Graves' disease and myasthenia gravis, in addition to D2T RA, with clinical trials proceeding as planned. Meanwhile, HanAll Biopharma shares surged 11,700 won, or 29.85%, to close at 50,900 won on the news.
